(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 2.36% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 87.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.67%.
Moderna's revenue in 2025 is $3,078,000,000.On average, 9 Wall Street analysts forecast MRNA's revenue for 2025 to be $749,308,471,859, with the lowest MRNA revenue forecast at $685,414,572,324, and the highest MRNA revenue forecast at $853,329,723,052. On average, 11 Wall Street analysts forecast MRNA's revenue for 2026 to be $984,947,234,171, with the lowest MRNA revenue forecast at $654,081,590,413, and the highest MRNA revenue forecast at $2,204,720,443,041.
In 2027, MRNA is forecast to generate $1,299,516,272,306 in revenue, with the lowest revenue forecast at $940,783,569,113 and the highest revenue forecast at $3,086,375,172,403.